Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex by John Pinching | Sep 14, 2022 | News | 0 Therapy is for the treatment of spasticity due to multiple sclerosis Read More
GW Pharma begins recruitment for US-based Sativex trial by Lucy Parsons | Nov 4, 2020 | News | 0 Trial will evaluate Sativex (nabiximols) for multiple sclerosis spasticity Read More
GW Pharma regains Sativex rights in UK by Anna Smith | Mar 3, 2020 | News | 0 The company is taking the reins back from Bayer. Read More
GW regains US rights to Sativex by Selina McKee | Dec 14, 2017 | News | 0 GW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka. Read More